Match Document Document Title
US20110136724 ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE  
There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as...
US20070232528 Formulation comprising histone deacetylase inhibitors  
The present invention relates to an orally available galenics formulation of Valproic Acid or derivatives thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum...
US20130028910 HMG1 ANTIBODY FOR TREATING INFLAMMATORY CONDITIONS  
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount...
US20090197805 Insulin receptor antagonists and related compositions, uses and methods  
Provided are new peptidic insulin receptor antagonists (PIRAs) and related compounds and compositions. Also provided are new uses of PIRAs and methods of obtaining PIRAs.
US20120064127 COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING OF CELLS  
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a...
US20100209502 Treatments Which Alleviate Functional Glycosylated Leptin Transport Factor for Controlling Weight and Obesity  
Methods and compounds for treating obesity and inducing weight loss use a functional, glycosylated leptin transport factor (LTF) polypeptide, referred to as fn/glyLTF. An unstable defective...
US20100311647 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY  
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the...
US20060058224 Methods of treating obesity with combination therapeutics  
Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension...
US20070166710 Methods for inhibiting adipogenesis and for treating type 2 diabetes  
The present invention relates to methods for inhibiting adieogenesis and methods for treating obesity, metabolic syndrome and non-insulin dependent diabetes mellitus by administering an agent that...
US20120093815 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20120052069 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20120003216 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20110195895 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20120122771 STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN  
The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly,...
US20060229237 Treatment of gastrointestinal distress  
A composition and method for treating and/or preventing acute and chronic gastrointestinal distress including nausea, vomiting, lactose intolerance, obstructive symptoms, diarrhea, mucositis,...
US20110065632 PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN-DOPAMINE CONJUGATES  
The present invention is directed to improvements in compositions containing a somatostatin-dopamine conjugate which retains both somatostatin and dopamine activity in vivo, methods for preparing...
US20110178005 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH OVERWEIGHT ANIMALS  
The invention encompasses compositions and methods for treating disorders and diseases associated with overweight. The application also encompasses genes differentially expressed in animals and...
US20090215702 Uv-Induced Dermatitis Inhibitor and Atopic Dermatitis Inhibitor  
At least one substance selected from the group consisting of a water-soluble peptide comprising at least one unit selected from the group consisting of an isoleucylglycylseryl unit, a...
US20100222276 PROTEASE-SENSITIVE SITE IN APOLIPOPROTEIN A1, THERAPEUTIC AND DIAGNOSTIC IMPLICATIONS  
The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific...
US20120003222 FZD8 EXTRACELLULAR DOMAINS AND FZD8 EXTRACELLULAR DOMAIN FUSION MOLECULES AND TREATMENTS USING SAME  
Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of...
US20110034372 TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE  
The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In...
US20140187479 BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM  
Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly...
US20110183886 MELANOCORTIN RECEPTOR LIGANDS  
The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more...
US20050159364 Copper antagonist compounds  
Copper antagonist compounds and the use of such compounds in methods for the treatment, prevention, or amelioration of various disorders that would be benefited by reduction in copper, for example...
US20120003233 HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR  
The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules,...
US20130137628 Dimeric Oxidation-Resistant Apolipoprotein A1 Variants  
An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer,...
US20070105759 Melanocortin receptor 4 (mc4) agonists and their uses  
The present invention relates to peptide agonists of the MC4 receptor, and as such are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes...
US20050163817 Biomatrix structural containment and fixation systems and methods of use thereof  
The containment and fixation system of the present invention generally includes a biomatix sleeve, biomatrix particles or combinations thereof made of a biomatrix material. The biomatrix material...
US20150031604 CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE  
The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13 I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1,...
US20130143796 CHIMERIC POLYPEPTIDES AND USES THEREOF  
The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating...
US20100323954 CHIMERIC POLYPEPTIDES AND USES THEREOF  
The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating...
US20120071400 LIPID METABOLISM-IMPROVING REAGENT  
Our objective is to provide a novel lipid metabolism-improving reagent effective in preventing and treating hyperlipidemia and obesity and to provide this reagent in food, beverages, nutritional...
US20090105136 NPY Y2 Agonist for Use as Therapeutic Agent for Disease Accompanied by Diarrhea  
An NPY Y2 agonist is used as a therapeutic agent for a disease accompanied by diarrhea. A compound capable of treating the disease can be evaluated and screened by examining the compound on the...
US20140154181 RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF  
The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or...
US20120231999 PEPTIDIC GLP-2 AGONISTS  
Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease.
US20100256057 METHOD OF PREVENTING OR TREATING BODY WEIGHT DISORDERS BY EMPLOYING CLUSTERIN  
Clusterin possesses an excellent anorexigenic effect and, accordingly, is useful for treating or preventing obesity or an obesity-related disorder. Co-administration of sub-clinical dose of...
US20150030594 BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES  
The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10,...
US20080221024 Analogs of Shk Toxin and Their Uses in Selective Inhibittion of Kv1. 3 Potassium Channels  
Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety,...
US20140234405 INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT  
To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and...
US20090183268 METHODS AND SYSTEMS FOR MEDICAL SEQUENCING ANALYSIS  
Disclosed are methods of identifying elements associated with a trait, such as a disease. The methods can comprise, for example, identifying the association of a relevant element (such as a...
US20110104315 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS  
The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders,...
US20110098216 THERAPEUTIC USES OF COLOSTRININ  
There is provided the use of Colostrinin for the treatment of obesity.
US20070160590 Metabolic uncoupling therapy  
A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic...
US20150216819 AGENTS USEFUL FOR TREATING OBESITY, DIABETES AND RELATED DISORDERS  
This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging,...
US20140120097 GENERATION OF NEW PANCREATIC BETA CELLS  
The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin...
US20150183843 GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF  
A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent...
US20140242089 GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF  
A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent...
US20080220097 FORMULATIONS CONTAINING CYNARA SCOLYMUS AND PHASEOLUS VULGARIS EXTRACTS WHICH ARE USEFUL IN THE TREATMENT OF OBESITY  
The present invention relates to a Cynara scolymus extract with a high content of caffeoylquinic acids, and a composition containing said Cynara scolymus extract with a Phaseolus vulgaris extract....
US20120322726 THERAPEUTIC AGENT FOR EATING DISORDERS  
Disclosed is a highly safe and effective therapeutic agent for eating disorders, which contains, as an active ingredient, a water-soluble fraction of a hydrolysis product of casein. The hydrolysis...
US20060234910 Methods for the treatment of insulin resistance and disease states characterized by insulin resistance  
The MINOR and TR3 genes are disclosed to be insulin responsive genes differentially expressed as a function of insulin resistance and Type 2 Diabetes in humans and a variety of well characterized...